MASH is the fastest-growing cause of liver transplants in the United States.

Now that hepatitis C can be easily cured, MASH has becoming one of the leading causes of liver cancer and liver transplants in the United States and worldwide. In 2022, about one third of liver transplant candidates with hepatocellular carcinoma had MASH.